Navigation Links
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Date:2/11/2008

ate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward- looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expe
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
2. Boston Scientific to Participate in Merrill Lynch Conference
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
5. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
6. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
7. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
8. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
9. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
10. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights ... colors, Valoya uses proprietary LED technology to incorporate their ... uniformity which is critical in low proximity installations. The ... throughout its lifetime which is up to four times ... "The investment cost was clearly higher when compared to ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that ... Board, to succeed Donald Fresne ; Mr. Fresne has ... a member of the Board.  In recognition of the many ... over almost twenty years, the Board designated Mr. Fresne as ... established a Search Committee to find a suitable replacement with ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... 2014 Once more, EMAAR has ... packaged waste water treatment plant to phase one of ... (KAEC). Two years ago Bioshaft successfully supplied and operated ... two residential towers with an occupancy of 900 residences. ... million gallons per day and was signed on September ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... a developer of sterile generic and specialty pharmaceutical products, ... A round of private financing. This financing was led ... very pleased that InnoPharma,s aggressive and well-managed growth over ... an outstanding investor, whose expertise and professional network will ...
... World-class investigators affiliated with US Oncology Research ... and displayed Dec. 6-10 at the Henry B. Gonzales ... Cancer Symposium ( SABCS ), an international scientific symposium ... in breast cancer. (Logo: http://photos.prnewswire.com/prnh/20110912/DA65711LOGO ) ...
... 2011  VIVUS, Inc. (NASDAQ: VVUS ) today announced ... of the company at the 2011 Deutsche Bank BioFEST Conference. ... Four Seasons Hotel, Boston, MA on Tuesday, December 6, 2011 ... of the presentation will be available at http://ir.vivus.com .About ...
Cached Biology Technology:InnoPharma Completes $15 Million Series A Financing 2US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 2US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 3US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium 4VIVUS to Present at the Deutsche Bank BioFEST Conference 2VIVUS to Present at the Deutsche Bank BioFEST Conference 3
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... syndrome (SARS), by its very name, indicates a disease ... brain tissue, causing significant central nervous system problems, according ... Clinical Infectious Diseases, now available online. , SARS, a ... reported in Asia in February of 2003. The disease ...
... evidence that the retina actively seeks novel features in ... to seek the unusual while ignoring the commonplace. The ... Nature on their finding that this principle of novelty-detection ... for novelty begins in the eye itself," says Markus ...
... that carbon nanotubes make an ideal scaffold for the growth ... doctors treat broken bones, allowing them to simply inject a ... The report appears in the June 14 issue of the ... world's largest scientific society. , The success of a bone ...
Cached Biology News:New study shows SARS can infect brain tissue 2Retina adapts to seek the unexpected, ignore the commonplace 2Nanotubes inspire new technique for healing broken bones 2Nanotubes inspire new technique for healing broken bones 3
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Recombinant Rhesus Macaque IFN-alpha...
chk 1 kinase...
Biology Products: